Dova Pharmaceuticals

General Information

We are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Our drug candidate, avatrombopag, which we acquired from Eisai, Inc., or Eisai, in March 2016, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that we are developing for the treatment of thrombocytopenia.

Employees: 7
Founded: 2016
Contact Information
Address 2530 Meridian Pkwy, Suite 300, Durham, NC, 27713, US
Phone Number (919) 806-4487
Web Address
View Prospectus: Dova Pharmaceuticals
Financial Information
Market Cap $424.8mil
Revenues $0 mil (last 12 months)
Net Income $-27.5 mil (last 12 months)
IPO Profile
Symbol DOVA
Exchange NASDAQ
Shares (millions): 4.4
Price range $17.00 - $17.00
Est. $ Volume $75.1 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ Leerink Partners
CO-Managers -
Expected To Trade: 6/29/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change